The Aliso Viejo, Calif-based company Avanir Pharmaceuticals Inc reports that results yielding from the first of a two-stage pharmacokinetic study centered on AVP-786 suggest that the drug exhibits a formulation comparable a pharmacokinetic, safety and tolerability profile to the drug AVP-923. The company notes that AVP-923 is a blend of two compounds, the active CNS ingredient dextromethorphan hydrobromide and a low-dose quinidine sulfate, which increases the bioavailability of dextromethorphan.
According to a recent news release, AVP-923 is currently being studied in several ongoing clinical trials that target neuropathic pain in multiple sclerosis (MS), behavioral symptoms of autism, agitation in Alzheimer’s disease, and levodopa-induced dyskinesia in Parkinson’s disease.
The release notes that in the current phase I study, AVP-923 was used as a control. The study is designed as a single-center, randomized, double-blind 2-way crossover to assess the pharmacokinetic profile, safety, and tolerability of single and multiple doses of AVP-786.
In an ongoing phase II clinical study of AVP-923 in central neuropathic pain in MS, the company adds that it will modify the enrollment target to 200 patients. The research is a component of the Pain Research in Multiple sclErosis (PRIME). The PRIME study is intended to evaluate the safety, tolerability, and efficacy of AVP-923 for the treatment of neuropathic pain in patients with MS. Avanir Pharmaceuticals reports that during the trial, eligible patients will receive one of three dose levels of AVP-923 containing either 45-milligram DM/10-milligram Q, 30-milligram DM/10-milligram Q, 20-milligram DM/10 milligram Q or placebo, daily for 12 weeks.
For more information on the trial, click here.
Source: Avanir Pharmaceuticals Inc
 |
 |
 |
 |
 |
Rehab Management is a pragmatic clinical and management magazine that features recent advances in the rehabilitation marketplace along with news and current issues in the rehab industry. Published ten times a year Rehab Management features an annual buyer's guide as well as an international issue. Rehab Management reaches your target audience: directors and administrators of rehab facilities, physical and occupational therapists, PTs in private practice, physiatrists, assistive technology providers, athletic trainers, sports medicine specialists, and other rehabilitation professionals. With a 20,000 circulation, Rehab Management offers special sections devoted to long-term rehab and rehab economics in addition to the multidisciplinary coverage, Rehab Management features informative feature stories, industry-leading facility profiles, financial issues, clinical approaches to rehab, legislative and technology updates, and much more. If you want to reach the decision-makers in the rehab field, you need to be seen in Rehab Management.
On Facebook
RSS